The journey of metformin from glycaemic control to mTOR inhibition and the suppression of tumour growth

Incidence of Dementia is Increased in Type 2 Diabetes and Reduced by the Use of Sulfonylureas and Metformin

(2018) Chih-Cheng Hsu et al.   JOURNAL OF ALZHEIMERS DISEASE

Long-Term Metformin Usage and Cognitive Function among Older Adults with Diabetes

(2018) Tze Pin Ng et al.   JOURNAL OF ALZHEIMERS DISEASE

Differential effects of metformin on age related comorbidities in older men with type 2 diabetes

(2017) Chen-Pin Wang et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study

(2017) John J. Bissler et al.   PLoS One

Metformin Protects Neurons against Oxygen-Glucose Deprivation/Reoxygenation -Induced Injury by Down-Regulating MAD2B

(2016) Xianfang Meng et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

Metformin in Amnestic Mild Cognitive Impairment: Results of a Pilot Randomized Placebo Controlled Clinical Trial

(2016) José A. Luchsinger et al.   JOURNAL OF ALZHEIMERS DISEASE

Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study

(2016) Jacqueline A French et al.   LANCET

Metformin increases PDH and suppresses HIF-1α under hypoxic conditions and induces cell death in oral squamous cell carcinoma

(2016) Talita Antunes Guimarães et al.   Oncotarget

Improved Muscle Function in Duchenne Muscular Dystrophy through L-Arginine and Metformin: An Investigator-Initiated, Open-Label, Single-Center, Proof-Of-Concept-Study

(2016) Patricia Hafner et al.   PLoS One

Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study

(2016) David N. Franz et al.   PLoS One

Dystrophin–glycoprotein complex regulates muscle nitric oxide production through mechanoregulation of AMPK signaling

(2015) Joanne F. Garbincius et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Metformin—mode of action and clinical implications for diabetes and cancer

(2014) Ida Pernicova et al.   Nature Reviews Endocrinology

Repositioning metformin in cancer: genetics, drug targets, and new ways of delivery

(2014) Mihaela Aldea et al.   TUMOR BIOLOGY

Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF-κB activation

(2013) Olga Moiseeva et al.   AGING CELL

Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

(2013) John J Bissler et al.   LANCET

Metformin limits ceramide-induced senescence in C2C12 myoblasts

(2013) Kavita S. Jadhav et al.   MECHANISMS OF AGEING AND DEVELOPMENT

Effects of Metformin on CD133+ Colorectal Cancer Cells in Diabetic Patients

(2013) Yanfei Zhang et al.   PLoS One

Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial

(2013) David Preiss et al.   Lancet Diabetes & Endocrinology

Targeting the Consequences of the Metabolic Syndrome in the Diabetes Prevention Program

(2012) Ronald B. Goldberg et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

O-Carboxymethyl chitosan nanoparticles for metformin delivery to pancreatic cancer cells

(2012) K.S. Snima et al.   CARBOHYDRATE POLYMERS

Renal tumours in a Tsc1+/– mouse model show epigenetic suppression of organic cation transporters Slc22a1, Slc22a2 and Slc22a3, and do not respond to metformin

(2012) Jian Yang et al.   EUROPEAN JOURNAL OF CANCER

Pharmacokinetics, tissue distribution and relative bioavailability of isoniazid-solid lipid nanoparticles

(2012) Rohit Bhandari et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Regulation of mTORC1 by the Rag GTPases is necessary for neonatal autophagy and survival

(2012) Alejo Efeyan et al.   NATURE

Therapeutic Trial of Metformin and Bortezomib in a Mouse Model of Tuberous Sclerosis Complex (TSC)

(2012) Neil Auricchio et al.   PLoS One

Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC

(2012) Giovanni Blandino et al.   Nature Communications

Weight change in people with type 2 diabetes: secular trends and the impact of alternative antihyperglycaemic drugs

(2011) C. Ll. Morgan et al.   DIABETES OBESITY & METABOLISM

Chronic AMPK activation evokes the slow, oxidative myogenic program and triggers beneficial adaptations in mdx mouse skeletal muscle

(2011) V. Ljubicic et al.   HUMAN MOLECULAR GENETICS

Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft

(2011) Jun Liu et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Metformin, Independent of AMPK, Inhibits mTORC1 in a Rag GTPase-Dependent Manner

(2010) Adem Kalender et al.   Cell Metabolism

AMPK-mediated regulation of transcription in skeletal muscle

(2010) Sean L. McGee et al.   CLINICAL SCIENCE

Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase

(2010) Carolyn Algire et al.   ENDOCRINE-RELATED CANCER

AMP-Activated Protein Kinase Inhibits IGF-I Signaling and Protein Synthesis in Vascular Smooth Muscle Cells via Stimulation of Insulin Receptor Substrate 1 S794 and Tuberous Sclerosis 2 S1345 Phosphorylation

(2010) Junyu Ning et al.   MOLECULAR ENDOCRINOLOGY

Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes

(2010) Kaixin Zhou et al.   NATURE GENETICS

Perinatal (Fetal and Neonatal) Tuberous Sclerosis: A Review

(2009) Hart Isaacs   AMERICAN JOURNAL OF PERINATOLOGY

Therapeutic targeting of mTOR in tuberous sclerosis

(2009) Julian R. Sampson   BIOCHEMICAL SOCIETY TRANSACTIONS

New Users of Metformin Are at Low Risk of Incident Cancer: A cohort study among people with type 2 diabetes

(2009) G. Libby et al.   DIABETES CARE

Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer

(2009) Sao Jiralerspong et al.   JOURNAL OF CLINICAL ONCOLOGY

Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis

(2009) Kristen Pollizzi et al.   Molecular Cancer

The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models

(2009) M. J. Williamson et al.   MOLECULAR CANCER THERAPEUTICS

Subependymal nodules, giant cell astrocytomas and the tuberous sclerosis complex: a population-based study

(2008) F J K O'Callaghan et al.   ARCHIVES OF DISEASE IN CHILDHOOD

The TSC1–TSC2 complex: a molecular switchboard controlling cell growth

(2008) Jingxiang Huang et al.   BIOCHEMICAL JOURNAL

Important role of the LKB1–AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice

(2008) Xu Huang et al.   BIOCHEMICAL JOURNAL

The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis

(2008) G.F.L. Hofbauer et al.   BRITISH JOURNAL OF DERMATOLOGY

AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint

(2008) Dana M. Gwinn et al.   MOLECULAR CELL

Sirolimus Therapy in Tuberous Sclerosis or Sporadic Lymphangioleiomyomatosis

(2008) D. Mark Davies et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis

(2008) John J. Bissler et al.   NEW ENGLAND JOURNAL OF MEDICINE